# Neoadjuvant Therapy With Ivonescimab Combined With Chemotherapy for Triple-Negative Breast Cancer

Source: https://onco.cc/trials/nct06977542/  
OnCo record `nct06977542` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of ivonescimab in triple-negative breast cancer, run by Fudan University, not yet recruiting.

## Summary

Neoadjuvant Therapy With Ivonescimab Combined With Chemotherapy for Triple-Negative Breast Cancer is a phase 2, interventional study registered as NCT06977542 by Fudan University, with a registry enrolment figure of 53 participants, started 2025-06 and due to reach its primary completion in 2029-01. Interventions recorded: Ivonescimab. Conditions listed: TNBC, Triple Negative Breast Cancer. Triple-negative eligibility wording from the registry: "Patients with Triple Negative breast cancer". No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-24
- Tags: ctgov-ingest; tnbc-deep-dive
- Registry id: NCT06977542
- Phase: 2
- Setting: A Single-Arm, Phase II Clinical Study of Neoadjuvant Therapy With Ivonescimab Combined With Chemotherapy in Patients With Early or Locally Advanced Triple-Negative Breast Cancer
- Sponsor: Fudan University
- Enrolled: 53

## Sources

- ClinicalTrials.gov NCT06977542: https://clinicaltrials.gov/study/NCT06977542

## Connected records

- cancers: [Early triple-negative breast cancer](https://onco.cc/cancers/tnbc-early/)
- technologies: [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/)
- drugs: [Ivonescimab](https://onco.cc/drugs/ivonescimab/)
- terms: [Triple-negative breast cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/tnbc-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct06977542.json